Prinzmetal angina

Summary

Prinzmetal angina (MONDO:0006021) is a disease and 6 clinical trials. Top therapeutic interventions include bisoprolol, diltiazem, and ascorbic acid. A subtype of coronary vasospasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 6

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	Prinzmetal angina
Mondo ID	MONDO:0006021
EFO	EFO:1000013
MeSH	D000788
DOID	DOID:0111151
ICD-11	563516749
SNOMED CT	87343002
UMLS	C0002963
MedGen	295
GARD	0007465
Is cancer (heuristic)	no

Also known as: angina inversa · variant angina

Disease family

This is a subtype of coronary vasospasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › vascular disorder › arterial disorder › coronary artery disorder › coronary vasospasm › Prinzmetal angina

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE4	3
Not specified	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01674686	PHASE4	UNKNOWN	The Effect of Sarpogrelate and High Dose Statin on the Reduction of Coronary Spasm
NCT03228238	PHASE4	TERMINATED	ANti-Oxidant in Variant Angina (ANOVA) Trial
NCT05294887	PHASE4	UNKNOWN	Randomized Trial to Examine a Differential Therapeutic Response in Symptomatic Patients With Non-obstructive Coronary Artery Disease
NCT01444885	PHASE2	COMPLETED	Evaluate the Efficacy and Safety of Pletaal (Cilostazol) in Subjects With Vasospastic Angina
NCT06992830	Not specified	ACTIVE_NOT_RECRUITING	Cardioneuroablation for Variant Angina
NCT06171893	Not specified	COMPLETED	Assessing the Effect of the ‘Wavy’ Application, on Stress and Burden of Disease in Women With INOCA

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BISOPROLOL	4	3
DILTIAZEM	4	3
ASCORBIC ACID	4	1
ATORVASTATIN	4	1
VITAMIN E	4	1
SARPOGRELATE	3	1
ALPHA-TOCOPHEROL	0	1